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 Parkinson’s Disease (PD) is a neurological movement disorder characterized by 
depletion of dopaminergic cell bodies in the substantia nigra pars compacta with 
subsequent loss of dopamine in the nigrostriatal pathway. PD is definitively diagnosed by 
the presence of intracytoplasmic inclusions in dopaminergic neurons. These inclusions 
are composed of a-synuclein aggregates, known as “Lewy bodies.” Lewy Bodies are 
known to be toxic to neurons leading to cell death. Individuals with PD most commonly 
manifest with bradykinesia (slowness in movement), tremors, and rigidity, but may also 
suffer orthostatic hypotension, dysphagia, anosmia, constipation, and sleep dysregulation.  
Mechanisms of PD pathogenesis may include defective protein handling, 
mitochondrial dysfunction, oxidative stress, and inflammation. Exposure to pesticides has 
long been implicated in the etiology of Parkinson’s Disease. An increasing number of 
epidemiological studies have linked the incidence of Parkinson’s Disease to 
environmental risk factors such as exposure to occupational pesticides and rural living 
where pesticides are known to leak into the soil and water systems far from their original 
area of use. The epidemiologic literature is lacking studies with large enough cohorts and 
accurate means to measure the exact pesticide exposure and duration of exposure. Given 
the extensive worldwide use of pesticides it is important to further study the associations 
between Parkinson’s disease and occupation exposures in larger populations.  
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Parkinson’s disease, a neurological movement disorder classified by the loss of 
dopaminergic (DA) neurons in the Substantia Nigra pars compacta (SNpc), is the second 
most common neurodegenerative disorder following Alzheimer’s disease in the U.S.1 It is 
characterized by resting tremor, bradykinesia, muscle rigidity, impaired gait and postural 
imbalance. PD patients may also exhibit cognitive dysfunction later in the disease.1 
Incidence of Parkinson’s disease increases with age and men are 1.5 times more likely 
than women to have PD.2 The Parkinson’s Foundation Prevalence Project estimates that 
930,000 people in the United States will be living with PD by the year 2020, which will 
rise to 1.2 million by 2030.2 According to a new study published by the Michael J. Fox 
Foundation with support from the Parkinson’s Foundation, the total economic burden of 
PD is nearly $52 billion each year.3 
 PD is diagnosed definitively by the presence of intracytoplasmic inclusions, 
known as Lewy bodies, in the degenerated dopaminergic neurons of the SNpc. These 
inclusions are composed of primarily alpha-synuclein protein aggregates. Various 
mechanisms of dopaminergic degeneration have been proposed and include defective 
protein handling, mitochondrial dysfunction, oxidative stress, and inflammation.4  
 Epidemiological studies have suggested that environmental factors may be 
involved in the mechanisms that can lead to dopaminergic nigral neuron degeneration in 
genetically susceptible individuals. This is otherwise known as the “double hit theory.” 
Chemicals are a commonly identified environmental risk factor for developing PD in the 
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future. In particular, pesticides and social factors that predispose one to pesticide 
exposure such as agricultural occupation, drinking well-water, and rural living have been 
implicated in PD. Studies have linked the mechanism of certain pesticides to 
parkinsonism and dopaminergic cell death using animal models. However, despite 
various epidemiological studies investigating pesticide exposure in humans, few have 
found significant associations between exposure to a specific pesticide and PD risk. 
Limitations include that individuals often experience poly-exposures and it becomes 
difficult to determine if one pesticide, or a combination, alter the risk for developing PD. 
Additionally, there is often a delay between exposure and symptoms making it difficult to 
identify a causal relationship especially for a specific pesticide or chemical.  
 
 
Statement of the Problem 
Animal studies provide compelling evidence that pesticide exposure may 
contribute to the development of PD. The organic pesticide rotenone has been found to 
lead to mitochondrial dysfunction and induce the behavioral and neuropathologic features 
of PD in some rodent models. In another animal study, exposure to a combination of the 
fungicide maneb and the herbicide paraquat in mice caused increased substantia nigra 
neuronal degeneration, subsequently producing parkinsonism behaviors.5 
Human evidence, however, is lacking to identify any particular pesticide 
compound, including those implicated by animal studies, as being responsible for causing 
PD. Various pesticide chemicals are sprayed across agricultural fields throughout the 
U.S. and worldwide. Pesticide use, particularly paraquat and rotenone, has remained in 
 
3 
popular use in the agricultural industry of the U.S. despite toxic teratogenic effects on 
animals. The environmental effects of pesticides are not limited solely to the regions 
sprayed but instead can absorb into the soil, as well as enter water systems. Thus, these 
pesticides may spread their toxic effects to vulnerable populations far from the regions of 
original use. These populations include agricultural farmers (licensed and unlicensed) and 
those living in rural communities. It is important to classify pesticide exposure risk to 
humans, especially if it is implicated in the pathogenesis of PD. 
 
Hypothesis 
Pesticide exposure, particularly the organic pesticide rotenone and the herbicide 
paraquat, is associated with an increased likelihood of PD.  
 
Objectives and specific aims 
This study will explore the association between pesticide exposure and development 
of sporadic PD in those most vulnerable to the effects of pesticide exposure. It will 
analyze a cohort of agricultural workers who are at highest risk of pesticide exposure 
occupationally. This study specifically aims to: 
• identify whether rotenone exposure is associated with a diagnosis of PD  
• identify whether paraquat exposure is associated with a diagnosis of PD 




REVIEW OF THE LITERATURE 
Overview of Parkinson’s Disease: 
Parkinson’s disease is a progressive neurodegenerative disorder characterized by 
motor and non-motor features that impact the functional status of those affected. 
According to the CDC, Parkinson’s disease is second only to Alzheimer’s disease as the 
most common age-related neurodegenerative disorder in the United States2. 
Approximately one million Americans are estimated to have Parkinson’s disease. This 
number surpasses the total estimated number of Americans affected by other progressive 
neurologic disorders including Multiple Sclerosis, Muscular Dystrophy, and 
Amyotrophic Lateral Sclerosis.1  
 
Early Discovery:  
British physician James Parkinson was the first to observe and describe what we 
now know are the classic symptoms of Parkinson’s disease. In 1817, he wrote “An Essay 
on the Shaking Palsy,” in which he described the main symptoms plaguing these patients: 
tremors, rigidity, and postural instability. In his essay he theorized that the “shaking 
palsy” developed due to a malfunction in the medulla region of the brain.6 Parkinson’s 
disease did not gain further recognition until 1861 when a French Neurologist, Jean-
Martin Charcot, distinguished the disease from other neurological conditions. Since this 
time, knowledge on PD and its pathophysiology has continued to grow. This has 
stimulated development of new and diverse treatment modalities in hopes of lessening the 





Incidence and Prevalence: 
It has taken several decades to compile evidence on the incidence and prevalence 
of Parkinson’s Disease. This may partly be due to poor reporting of PD cases and 
difficulty reaching patients affected by PD across the US and the world. Data on 
prevalence is important for estimating the economic and social burden of the disease. 
Medical records or health system claims data are most commonly used to estimate PD 
prevalence. These can be limited by diagnostic misclassification and misreporting or 
underreporting of cases. An example of underreporting is when end stage patients who 
have further progressed in the disease are unable to follow up in clinic.   
 
In efforts to better coordinate epidemiological investigations of the disease, the 
Parkinson’s Foundation established the Parkinson’s Foundation Prevalence Project (P4 
Project) in early 2014. The P4 Project combines data from four different regions across 
North America and compares these estimates to nationwide Medicare data to ensure 
accuracy.7 The Parkinson’s Foundation Prevalence Project Study estimates that 930,000 
people in the U.S. will be living with PD by 2020. This number is expected to rise to 1.2 
million by 2030. In comparison, the last study to investigate the prevalence and incidence 
of PD was conducted in 1978. This new study nearly doubles that previous study’s 
prevalence number by drawing cases from larger and more diverse populations.7  
Additionally, the study confirmed that men are at higher risk for PD than women and PD 






Parkinson’s Disease is characterized pathologically by the chronic loss of 
dopaminergic neurons found in the nigrostriatal pathways of the brain, specifically the 
Substantia Nigra Pars Compacta (SNpc). However, neurodegeneration is not limited 
solely to these nigrostriatal dopaminergic neurons. Rather, neurodegeneration also 
involves cells located in other regions of the basal ganglia, thalamus, and cortex.8 PD 
progression and the significance of dopaminergic neuron loss must be taken in context of 
the role of dopamine in producing movement. 
Dopamine is a neurotransmitter synthesized and released by certain neurons in the 
brain. It is classified as a catecholamine and is synthesized by decarboxylation of its 
precursor chemical, L-DOPA. L- DOPA is produced by hydroxylation of its precursor 
tyrosine by the enzyme tyrosine hydroxylase. The brain exhibits several important 
dopamine-signaling pathways associated with pleasure and reward, motivational and 
emotional responses, as well as coordination of movement. 
Figure 1: Dopamine Synthesis Pathway9 
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The mesolimbic pathway, for example, plays a major role in what is known as the 
pleasure and reward pathway. This pathway originates with dopaminergic cell bodies in 
the ventral tegmental area (VTA), a dopamine-rich nucleus located in the midbrain. 
Dopaminergic axons project from the VTA and primarily terminate in the Nucleus 
Accumbens (NAc) of the ventral striatum. Dopamine acts as a signaling agent in the 
brain to form reward-related memories. This means neurons that release dopamine are 
activated when we expect to receive a reward. Anticipation of specific rewards may come 
in many forms for different individuals but it is the anticipation for the reward that serves 
to increase the levels of dopamine release from the VTA. Drugs of abuse, such as 
cocaine, become addictive by upregulating the neurons that regulate this very reward 
pathway. This is what causes the euphoric feeling experienced immediately after taking a 
drug, ultimately motivating someone to use the drug again.10 This same system is 
implicated in one of the side effects experienced by patients taking dopaminergic 
medications used to treat their PD. Patients report a surge in their impulsivity while 
taking high dose dopamine agonists or levodopa, including hypersexuality, increased 
gambling, and other socially detrimental side effects due to a stimulation of this reward 
pathway.11  
The VTA is located near another dopaminergic-rich nucleus called the Substantia 
Nigra. The Substantia Nigra coordinates motor activity through its dopaminergic axon 
projections primarily to the dorsal Striatum. This is called the mesostriatal pathway.10  
Although dopamine plays a multitude of roles outside of the central nervous system, the 
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main focus of this overview will be the dopamine dependent circuit of the brain that 
mediates voluntary motor control and executive functions.  
 
The Basal Ganglia 
The Basal Ganglia are a group of subcortical nuclei found deep within the 
cerebral hemispheres, primarily responsible for motor control but also involved in motor 
learning, executive function, and emotions. They include the Striatum (Caudate and 
Putamen), the external and internal segments of the Globus Pallidus (GPe, GPi), the 
Subthalamic Nucleus (STN), and the Substantia nigra with its pars reticulara (SNpr) and 
pars compacta (SNpc) (Figure 1). All of the input from the motor cortex related to the 
planning and execution of movement projects to the Basal Ganglia, specifically to the 
striatum, using the excitatory neurotransmitter glutamate.  
The Basal Ganglia and Surrounding Structures: Figure 2: The Striatum includes two 
regions called the Caudate Nucleus and the Putamen. Located medial to the Putamen is 
the Globus Pallidus, which is divided into external (GPe) and internal (GPi) segments. 
Striatal neurons receive cortical inputs and project to the GPi. The GPi delivers the output 
neurons of the BG, projecting to the motor thalamus which in turn projects back to the 









Disruption of the basal ganglia network has been implicated in several movement 
disorders, including Parkinson’s Disease. The functional neuroanatomy of the Basal 
Ganglia allows information to flow between the basal ganglia and the cortex through two 
distinct pathways in order to produce movement.12  These are known as the direct and the 
indirect pathway. These two pathways have opposite effects on motor activity and help 
explain many clinical symptoms of basal ganglia diseases.13  
 The direct pathway (Figure 2) begins when cortical projections excite striatal 
neurons using the excitatory transmitter glutamate. The striatal cells in turn signal 
through the inhibitory transmitter GABA along inhibitory projections directly to the GPi. 
At baseline function, the GPi projects to the thalamus also using the inhibitory 
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neurotransmitter GABA. Additional inhibition of the GPi comes from the striatum and 
premotor cortex. Inhibition of the GPi releases its baseline inhibition on the motor 
thalamus. This dis-inhibition increases the excitatory activity of the thalamus on the 
motor cortex. Overall, the direct pathway results in dis-inhibition of the thalamus, which 
in turn stimulates the motor cortex to increase movement.8 
 
Figure 3: Direct Pathway of the Basal Ganglia (Adapted from Kenhub: Connections 






In contrast, the indirect pathway functions by further inhibiting the thalamus from 
communicating to the motor cortex and as a result decreases movement. This pathway 
also starts when the motor cortex stimulates the striatal neurons via the excitatory 
neurotransmitter glutamate (Figure 3). The difference is the striatal neurons project their 
GABA inhibitory signals to the GPe instead of the GPi. Once inhibited, the GPe releases 
its baseline inhibition on the subthalamic nucleus (STN), which can now send its 
projections to the GPi. Once dis-inhibited, the subthalamic nucleus increases its 
excitatory stimulation on the GPi resulting in more GABA/inhibitory activity from the 
Gpi on the thalamus. This ultimately results in an increase on inhibition of the thalamic 
neurons and, in turn, the thalamus is unable to stimulate the motor cortex and overall 
decreases movement.8 The fine balance between the direct and indirect pathways are 
thought to ultimately result in smooth, precise, voluntary human movements necessary to 
maintain normal daily function. 
 
Figure 4: Indirect Pathway of the Basal Ganglia (Adapted from Kenhub: 







One way in which these pathways are adjusted is through the neurotransmitter 
dopamine, which is produced in the Susbtantia Nigra pars compacta and modulates its 
effect via dopamine receptors. When the nigrostriatal neurons release dopamine into the 
striatum, the neurotransmitter has an excitatory effect on D1 receptors, stimulating the 
direct pathway. Dopamine also has an inhibitory effect on the striatum via D2 receptors, 
down regulating the indirect pathway and decreasing its inhibition on motor activity. 
Thus, the cumulative effect of dopamine in the nigrostriatal pathway comes from signaling 
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both the direct pathway and the indirect pathway to increase coordinated motor 
movements.8 
The hallmark of Parkinson’s Disease is deposits of Lewy bodies, inclusions of 
abnormal protein aggregates, within dopaminergic neurons. These deposits are made up 
of insoluble fibrillary aggregations of lipids and misfolded proteins, primarily alpha-
synuclein. The exact cause of said protein aggregation remains unknown, but its toxic 
effects are known to mediate disruption of cellular homeostasis and neuronal death. 
. 8 α-Synuclein protein overproduction increases the risk of PD in both familial and 
sporadic cases. For example, families that have been found to have multiple deficient 
copies of the SNCA gene, which encodes for alpha-synuclein, develop early onset PD 
and variants with higher expression of the deficient SNCA gene are associated with 
increased risk of PD.4  
Research also suggests that mitochondria may play a role in the development of 
PD. Malfunctioning mitochondria are major sources of free radicals. Free radicals are 
molecules that deliver oxidative stress to cells; they destroy membranes, proteins, DNA, 
and other parts of the cell. Oxidative stress-related changes, as well as mutations 
affecting mitochondrial function, have been found in the brains of individuals with PD. 14 
A combination of research and autopsy studies suggest that loss of dopaminergic 
neurons in the Substantia Nigra pars compacta (SNpc) occurs concurrently with the 
accumulation of alpha-synuclein into Lewy Bodies. When the neurons in the substantia 
nigra degenerate, the subsequent loss of dopamine results in a disturbance in the balance 
of activity between the direct pathway and the indirect pathway with an overall reduction 
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in movement.8 This results in the hallmarks of bradykinesia and rigidity associated with 
PD.   
 This etiological theory is further supported by the alleviating effects of dopamine 
replacement therapy, such as the use of levodopa, on the motor symptoms of PD. It 
initially resolves the motor symptoms of PD as it replenishes the dopamine levels that are 
lost and reinstitutes the direct pathway, as well as inhibition of the indirect pathway. 15 
 
Diagnosis: 
Diagnosis of Parkinson’s Disease is based primarily on clinical symptoms and, 
thus, requires a high index of suspicion early on in disease. According to the International 
Parkinson Disease and Movement Disorder Society diagnostic criteria, PD diagnosis 
requires the presence of two of the following features: resting tremor, rigidity, 
bradykinesia and/or postural instability. These criteria have been published with the 
recognition that they can only lead to a diagnosis of probable PD. A definitive diagnosis 
of PD requires histopathological identification of α-synuclein-containing Lewy bodies 
(LBs) or Lewy neurites, which can only be identified on post-mortem autopsy.8  
 
Tremor 
The most commonly recognized symptom of PD is the characteristic “pill-rolling” 
tremor that appears at rest. It often begins in the hand and is unilateral early on in the 
disease. The tremor may disappear during sleep or improve with intentional movement 
early on in the disease.14 It can then re-emerge as the patient holds their hands in one 
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position or at the end of activity. It is often visible with walking or when the individual is 
under stress.  
 
Rigidity 
Rigidity, or resistance to voluntary movement, also affects most people with 
Parkinson’s disease. An individual with this symptom may describe their muscles aching 
and remaining constantly tense or stiff. It can also present as pain in the joints due to the 
stiffness of the muscles with attempted movement. When PD is suspected, providers will 
often check for rigidity by passively trying to move the patient’s arm fluidly. The positive 
or abnormal sign characteristic for PD is the production of short, jerky movements known 
as “cogwheel” rigidity. 14  
 
Bradykinesia 
Bradykinesia, slowness of movement, is the defining symptom of Parkinson’s 
disease. This can be seen early in disease as difficulty with fine motor movements such as 
opening jars or buttoning shirts. Facial movement slowness makes patients appear to be 
wearing a mask. On exam, decreased arm swing with walking and slow, low amplitude 
fine movements are characteristic. Bradykinesia makes daily activities and simple tasks 
both difficult and frustrating to accomplish. 
 
Postural Instability 
Postural instability, or tendency to lose balance easily,  may  cause individuals to 
fall easily, leading to further morbidity and mortality in PD patients. 14 Often this presents 




Atypical symptoms, such as cerebellar signs, early severe autonomic dysfunction, vertical 
supranuclear palsies, or cortical sensory loss, are usually absent; their presence would be 
indicative of an alternative diagnosis. An asymmetric onset of symptoms and a good 
response to levodopa are supportive for a diagnosis of PD and are the two most important 
features to discriminate PD from other variants of parkinsonism, as the latter do not 
respond to Parkinson medications.14 
A number of non-motor symptoms may also affect patients with Parkinson’s 
Disease. Depression, emotional changes, low speaking volume, urinary problems, 
constipation, sleep problems, in particular REM behavior disorder, orthostatic 
hypotension, loss of smell, and dementia may affect individuals with PD over the time 
course of their disease. These can be difficult to treat and have a significant impact on 
their quality of life.14 Many times these symptoms are present at diagnosis, in particular 
REM behavior disorder and anosmia, but are unrecognized by patients and providers as 
related to the motor disease.16(p)  
 
 
Disease Progression and Classification 
 
Progression of PD: 
The progression of Parkinson’s disease is a complex process involving host gene 
susceptibility and environmental factors. Research suggests that progression first affects 
the dorsal motor nucleus of the vagus nerve along with the olfactory bulbs, then the 
Locus Coeruleus, and eventually the Substantia Nigra. This sequence of events, also 
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called the Braak Hypothesis, may explain why many patients lose their sense of smell 
(mediated by the Olfactory Nerve) early on in the disease before any signs of motor dis-
regulation.17  
As disease progresses, so does the severity of motor and non-motor symptoms. 
PD is a widely heterogeneous disease and there have been attempts to subclassify the 
disease. Although a consensus has yet to be met, one sub classification, primarily based 
on clinical characteristics, suggests two subtypes: a tremor dominant PD and an akinetic 
rigid form. A patient with tremor dominant PD can have milder additional concerning 
motor symptoms and in general responds better to dopamine replacement therapy. In 
contrast, a patient with a akinetic-rigid form of PD lacks tremor and has significant 
postural instability, as well as an increased incidence of non-motor features. The course 
of the disease and prognosis differs depending on subtype, making therapy an 
individualized approach as severity increases. Interestingly, the differences in 
classification of the disease also suggest distinct pathogeneses and etiologies to PD.18  
 
Demographics: gender, age, ethnicity  
 
Several non-modifiable risk factors are associated with an increased risk of 
developing Parkinson’s disease, including gender, age, ethnicity, and race. For instance, 
the incidence of PD is higher among men than women. One theory suggests estrogen may 
exhibit neuroprotective effects, which is supported by the finding that women who have 
had multiple births show a reduced risk of developing PD. Another theory suggests men 
are at higher neurodegenerative risk because they are more likely involved in minor head 
trauma and exposure to occupational toxins.19  
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 The prevalence of PD increases with age, affecting one percent of the population 
over the age of 60. This risk increases to 5 percent in the population over the age of 85. 
There have been cases of PD diagnosed before the age of 50 and is known as early onset 
PD. Diagnosis before the age of 20 is very rare and is considered Juvenile PD. Genetic 
mutations, such as those in SNCA gene, are more likely to be implicated in early onset 
and Juvenile PD cases.20  
 Studies have found that PD is more common in Caucasians than in African 
Americans or Asians. Interestingly, the highest incidence of PD is found to be in 
Hispanics. One analysis found the incidence of PD in Hispanics to be 16.6 per 100,000 
persons compared to 13.6 per 100,000 non-Hispanic Whites, 11.3 per 100,000 Asians, 
and 10.2 per 100,000 Blacks.21  
 
Genes implicated in PD 
PD can be classified as familial, genetically inherited in an autosomal dominant or 
recessive pattern, or as sporadic, developing due to an unknown etiology such as 
cumulative environmental exposures. Genetically inherited PD accounts for 
approximately 10-15% of all PD cases and the remainder of cases are classified as 
sporadic or environmentally related. 22 
 Several genes have been identified that are mutated in familial PD, including 
alpha-synuclein (SNCA), glucocerebrosidase (GBA), leucine-rich repeat Kinase 2 
(LRRK2), vacuolar protein sorting-associated protein 35 (VPS35), parkin RBR E3 
ubiquitin protein ligase (PARK2), phosphatase and tensing homolog-induced kinase 1 
(PINK1), and Parkinson protein 7 (PARK7).22  
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 Many of these gene mutations are found to encode for proteins that function to 
protect cells from oxidative stress and mitochondrial dysfunction. For example, the 
parkin gene is translated into a protein that normally helps break down and recycle 
dysfunctional proteins. PINK1 codes for a protein active in mitochondria and protects 
cells from oxidative stress. Interestingly, the Parkin gene and PINK1 work together in a 
common pathway to regulate mitochondrial function. When mitochondria cells are 
damaged, PINK1 accumulates in the outer membrane of the dysfunctional mitochondria. 
PINK1 serves as a recruitment signal to the Parkin E3 ubiquitin ligase activity, which 
triggers selective autophagy of the defective mitochondria. Understanding the 
mitochondrial biological pathways may serve researchers to better understand when these 
pathways go awry in Parkinson’s disease.23  
 
 
Modifiable Risk Factors for PD 
Large population studies have identified some modifiable risk factors for PD. 
Interestingly, a number of studies worldwide have consistently found that cigarette 
smoking is associated with a reduced risk of PD. Risk in those that have ever smoked is 
half of that in those that never have with a clear dose-response relationship. Nicotine has 
been shown to be protective against nigrostriatal damage in animal models. However, it 
is unclear if nicotine is directly responsible for this protective effect or whether one of the 
hundreds of additional compounds found in a cigarette smoke may also modify PD risk. 




 Caffeine consumption, in particular through coffee, has also been consistently 
associated with a reduced risk of PD in epidemiological studies. A dose-response 
relationship is seen with caffeine consumption similar to cigarette smoking. Several 
animal studies suggest caffeine may protect dopaminergic neurons through antagonism of 
the adenosine A2A receptor, a receptor commonly expressed by dopaminergic neurons. 
Caffeine renders the A2A receptor inactive and, therefore, may halt progressive 
destruction of dopamine neurons expressing this receptor.4 A study conducted at 
Massachusetts General Hospital found that mice pretreated with caffeine retained near 
normal dopamine levels when exposed to chemicals known to induce parkinsonism 
effects by degenerating dopaminergic neurons.   
 
Disease Progression and impact on morbidity 
 
As the disease progresses, motor symptoms worsen with the onset of further 
complications associated with long-term levodopa therapy. These are more difficult to 
manage and include non-motor fluctuations, dyskinesias, and psychosis. In an advanced 
disease stage, both motor and non-motor symptoms may become resistant to current 
medications. Postural instability and freezing of gait may lead to falls and fractures, while 
dementia and hallucinations can develop in some patients, which often warrant nursing 
home placement.18 
 
Non-motor symptoms are common in early PD but also progress and become 
more challenging to manage. Autonomic symptoms, such as orthostatic hypotension, can 
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be difficult to treat causing significant problems for patients, leading to falls and repeat 
hospitalizations in many patients. While medication can be used to treat orthostatic 
hypotension, it can become refractory in late disease. Dementia occurs in 83% of patients 
with PD after 20 years of disease progression. Unfortunately, there is no good treatment 
for dementia and this is an irreversible consequence. Psychosis and hallucinations are 
also known to occur in a mild form early on in the disease, but worsen with increased 
medication use and greatly impact quality of life for the patient and caregiver. These non-
motor symptoms understandably cause significant disability and impact morbidity. 
Patients may require family members to assist in their care or  admission to nursing 
homes.18 
 
Medical Therapies  
 
Treatment predominantly focuses on symptomatic relief of motor symptoms with 
drugs aiming to either restore the level of dopamine in the striatum or mimic the effects 
of dopamine by acting on striatal post-synaptic dopamine receptors.  
 
The first therapy developed for PD is the drug combination levodopa/carbidopa 
(L-dopa). L-dopa is used at all stages of PD and continues to be the most potent and 
efficacious medication available. Dopamine cannot cross the blood-brain barrier so 
patients cannot simply take a dopamine replacement pill, as dopamine would accumulate 
peripherally resulting in significant nausea and vomiting.  Instead carbidopa allows 
levodopa to pass the blood brain barrier and only then is levodopa converted to 
 
22 
dopamine. Although levodopa is not a cure, it offers a short-term replenishment of the 
lost dopamine levels secondary to the degeneration of substantia nigra. As a result, it is 
successful in treating the tremors and other motor symptoms early on in the disease. This 
therapy can be maxed to an individual’s need but at higher doses may produce 
dyskinesia, involuntary muscle movements such as twitching or writhing, and worsen 
hallucinations or orthostatic hypotension.18  
 In addition to L-DOPA, dopamine agonists, MAO-B inhibitors, COMT inhibitors, 
A2A agonists, amantadine, and anticholinergics can be used as alternative or adjunctive 
therapies. These drugs all have distinct mechanisms of action serving to mimic dopamine 
effects by acting directly on dopamine receptors and/or decreasing the breakdown of 
endogenous dopamine in the brain.14  
 
 
Epidemiological evidence links of pesticide exposure to PD: 
 
The identification of several genes related to PD has provided scientists with clues 
about the molecular mechanisms involved in its pathogenesis. However, evidence is 
lacking for one clear or direct genetic etiology. Abnormal accumulation of alpha-
synuclein is implicated in the histopathology of PD, however, these aggregates are 
present in those with Parkinson’s associated gene variants and also in those without any 
identifiable genetic variants. This has led researchers to focus on the theory of 
environmental factors playing a role in the etiology or even more likely the effects of 
environmental interactions on genes. New research has been largely devoted to the 
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biological and epidemiological evidence of genetic risk factors and environmental 
exposures.  
 Investigations into the endogenous metabolism of neurotoxins have also 
encouraged studies into the effects of pesticides on PD risk. In fact, an increasing amount 
of epidemiological evidence has linked exposure to pesticides, farming, well-water 
drinking, and rural living with an increased risk of PD.25 Such studies have proposed that 
pesticides lead to the onset or acceleration of developing chronic parkinsonism due to 
their effects on oxidative stress, interference with dopamine transporters, mitochondrial 
dysfunction, promotion of alpha-synuclein fibrillation, and inflammation.25 
 Pesticides in the United States are mainly used in agriculture but a substantial 
portion are also used in houses, yards, parks, golf courses, and swimming pools. 
Furthermore, pesticides are not limited to area of exposure. They may become airborne, 
absorb into soil, enter bodies of water, or be taken up by plants and animals.26 The 
National Academy of Sciences estimates that between 4,000 and 20,00 cases of cancer 
are caused per year by the amount of pesticides used in food.  
 Once sprayed into its environment, a pesticide can have a range of environmental 
effects depending on how long it lasts before being broken down. Together, this poses a 
risk for pesticides to enter our water systems, including fresh water sources such as 
rivers, streams, and even wells. The U.S. Department of Agriculture and U.S. Fish and 
Wildlife Service estimate that between 6 and 14 million fish are killed by pesticides each 
year. They also estimate that more than 67 million birds are killed from pesticide use 




Parkinson's disease and pesticides: biological plausibility 
 
MPTP toxicity linked to acute parkinsonism 
Discovery of the relationship between pesticides and PD dates back to the 1980s 
when exposure to the chemical MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) 
was found to result in degeneration of dopaminergic neurons. MPTP is a dopamine 
neurotoxin that crosses the BBB and is metabolized by monoamine oxidase-B (MAO-B) 
into its toxic form MPP+. MPP+ is then taken up by the dopamine transporter into the 
dopaminergic neuron where it exhibits its neurotoxic effects and leads to dopaminergic 
cell death, mainly by inhibiting the mitochondrial complex I (Figure 5).  
 




This crucial discovery was first made in 1982 when IV drug users in San Jose, 
California presented to local emergency rooms with “acute parkinsonism” after injecting 
with MPTP, an unintended and harmful byproduct of attempted heroin production. They 
manifested the classic motor symptoms of chronic, advanced Parkinson’s Disease, 
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symptoms that substantially improved with L-Dopa treatment. IV administration of 
MPTP to monkey models produced the same acute onset of parkinsonism as that 
observed in humans. Researchers found that in its neurotoxic form, MPP+ caused 
selective degeneration of the dopaminergic neurons in the Substantia Nigra. This toxic 
metabolite has since been investigated in several mice and non-human primate studies.4 
Now researchers and environmentalists alike investigate agents with similar structures 
and toxic profiles as MPTP.   
 Subsequently, the discovery of structural similarities between MPTP to the 
herbicide paraquat has stimulated investigations into paraquat as another potential 
neurotoxin. In fact, animal studies have suggested that pesticides with related structural 
properties to MPTP, such as rotenone, maneb, dieldrin, heptachlor and atrazine, may be 
linked to a-synuclein accumulation and dopaminergic cell degeneration in the substantia 
nigra.27  
 
Paraquat known to increase oxidative stress 
Investigations have found that Paraquat also exhibits neurotoxic effects on 
dopaminergic cells. Paraquat can cross the BBB and, after it is converted into Paraquat+, 
is taken up into nigral dopaminergic terminals via the dopamine transporter. Paraquat+ 
increases generation of reactive oxygen species (ROS) through production of superoxide 
radicals and redox cycling. Animals treated with Paraquat+ showed increased lipid 
peroxidation, decreased levels of antioxidants, impaired mitochondrial function, 
increased expression of α-synuclein aggregates, and ultimately motor symptoms of PD. 
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Interestingly, paraquat+ selectively killed nigral dopaminergic neurons. This relative 
selectivity may be explained by nigral dopaminergic neurons exhibiting increased 
sensitivity to oxidative stress.4  
 According to the CDC, Paraquat was first produced for commercial use in 1961. 
Paraquat has been either already banned or is in the process of being restricted in 32 
countries including China, Brazil, and those of the European Union. Paraquat, however, 
continues to be in full use in the United States. In the U.S. paraquat is classified under 
“restricted use” meaning it can only be used by licensed applicators. The Environmental 
Protection Agency (EPA) has admitted to the lethal risks paraquat poses to humans and 
animals but continue to discount evidence that paraquat may cause the onset or accelerate 
development of PD. The California Environmental Protection Agency states that paraquat 
can penetrate the nervous system, is a neurotoxicant, and impacts brain functions.26  
Once sprayed, Paraquat binds strongly to particles in the soil. It’s half-life in soil can be 
up to 20 years and is predicted to be even greater in water sources.26  
 
Rotenone causes mitochondrial complex I disruption 
 
Rotenone is a mitochondrial toxin that inhibits Complex I of the mitochondrial 
electron transport chain. This is the same site inhibited by the neurotoxin MPP+ that 
causes parkinsonism. Rotenone is considered a natural pesticide that is produced by 
several plant species and has been used by indigenous cultures for hundreds of years. It is 
still used in our freshwater systems today to eradicate invasive fish species. Animal 
studies have shown that rotenone contributes to many of the mechanisms implicated in 
PD, including mitochondrial dysfunction, impaired ATP production, increased 
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generations of ROS, and inhibiting proteasome function. More importantly, like MPTP, it 
causes selective degeneration of dopaminergic neurons in the Substantia Nigra. Rotenone 
also promotes accumulation of intracellular a-synuclein aggregates leading to symptoms 
of bradykinesia, rigidity, and tremors in animal models. Rotenone is known to cross the 
blood brain barrier, but a recent study found that it may also act in the gut by promoting 
synuclein aggregation in the enteric nervous system cells and then spreading to the CNS 
via retrograde axonal transport.4This finding would support the Braak Hypothesis for PD 
and suggest that rotenone could be a triggering exposure. 
 Rotenone has a short half-life once sprayed in the environment and is not known 
to bioaccumulate as paraquat does. However, in animal models rotenone has exhibited 
progressive pathologic effects with relatively brief durations of exposure.4 
 
Existing research 
Several epidemiologic studies in the past decade have supported the hypothesis 
that pesticide exposure is associated with an increased risk of PD. The goal of such 
studies was to provide evidence that PD results from the interaction of genes and 
environmental exposures – the two-hit hypothesis. Researchers are now focusing on 
better defining exposure characteristics in susceptible populations, especially those 
working with pesticides on an agricultural level. Epidemiologic studies measuring the 
link between pesticide exposure and PD risk have differed in their design, in definition of 
cases, in assessment of pesticide exposure, and in the selection of controls.  
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 The Parkinson Environment Gene (PEG) study investigated the influence of 
occupational pesticide use on PD in a population susceptible to various occupational, 
residential, and household sources of pesticide exposure. Using a case-control approach 
they recruited 360 PD cases and 827 controls from rural California counties (Kern, 
Fresno, and Tulare). PD cases were confirmed by UCLA Disorder Movement 
Specialists.28  
 Participants often do not know or remember what active ingredients are contained 
in the product they used. Thus, to minimize reporting bias the researchers compared 
reported pesticide brand names, purposes, and dates of use with information in the 
California Department of Pesticide Regulation (CDPR) database to identify the main 
active pesticide ingredients in the reported pesticide products. They also used the mini 
mental status exam (MMSE) to restrict inclusion to participants with the highest scores in 
order to minimize the effects of cognitive impairment on accurate reporting.  
 They found using any pesticide occupationally for more than 10 years doubled the 
odds of PD compared with no occupational pesticide use after adjusting for sex, smoking, 
age, education, and race (OR=2.50, 95% CI: 1.50, 4.15). When comparing individual 
pesticide product types, they found insecticide use, such as rotenone, was associated with 
increased PD risk (OR=2.10, 95% CI: 1.22, 3.60). This was also true for herbicide use, 
such as paraquat (OR=2.45, CI: 1.37, 4.36). These OR values are high because the 
analysis combined multiple sources of pesticide exposure. However, values remain 
significant when breaking down sources of exposure by household (OR=1.46), ambient 
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residential (OR=1.56), ambient workplace (OR=1.68), and occupational pesticide use 
(OR=1.50).28  
 Surprisingly, they also found that those with occupational pesticide use who 
reported using any PPE (gloves, masks, coveralls, applying pesticides in an enclosed cab, 
and other sorts of protection, such as boots, goggles, etc) were at highest risk of PD 
(OR=1.62, 95% CI: 1.00, 2.60), suggesting a failure of PPE to protect those exposed 
from pesticides neurotoxic effects. However, they did not collect information on what 
defines accurate PPE wear, such as whether glove users wore the appropriate chemically 
resistant gloves or gloves inadequate for protection from exposure (i.e. if gloves used 
were clean and/or in good condition). They also did not comment on if PPE use was 
100% of the time or less.28 Thus, this variable was not defined properly in the study. 
Additionally, those using PPE may have been inadvertently exposed to the highest 
concentrations of pesticides due to false sense of security. Another possibility is their 
exposures to pesticides were higher than other works hence the need for PPE.  
 A weakness of this study, like many epidemiological studies on pesticide 
exposure, is that investigators relied on self-reporting. Retrospective self-reporting of 
exposures is the most common method of estimating pesticide exposure but has the 
potential for recall bias. Cases and controls may remember the pesticide names/classes or 
duration of exposures incorrectly. Those with PD symptoms are more likely to recall or 
over report a pesticide exposure through occupation than not. This could implicate a non-
differential bias and lead the study to have a null-effect. This study may also lack 
generalizability because it looks at mostly white, European descent, males who reported 
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only occupational exposures, excluding other races, particular migrant workers and 
farmers, females, and those who may have been exposed at home.   
 Additionally, the authors of this study acknowledge that co-exposure to multiple 
pesticides made it difficult to narrow down increased risk of PD to one particular 
pesticide and, when adjusted for, their CI widened (OR=4.46, 95% CI: 0.66, 30.25).28 
The exposure to one pesticide is often confounded by exposure to other pesticides, 
making it difficult to identify the true causative agent. To combat this, more recent 
epidemiologic studies have begun to group pesticides that are believed to act through 
common neurotoxic mechanisms in order to investigate their associations with PD.  
 
Another study by Tanner et al. chose to classify pesticide exposures by presumed 
mechanism of neurotoxicity (i.e. mitochondrial dysfunction vs. oxidative stress) rather 
than by their chemical class (i.e. herbicides vs. organochlorines). Using a nested case-
control methodology, they recruited 110 PD cases and 358 controls from the larger 
Agricultural Health Study (AHS).5 The AHS was a prospective study including 84,740 
private pesticide applicators (mostly farmers) recruited in 1993–1997 in Iowa and North 
Carolina and their spouses.29 Some strengths to this study include the focus on an 
agricultural worker population, organized pesticide exposure data, and the quality of 
diagnosis performed.  Using computer assisted telephone interviews, investigators 
obtained details on pesticide use from 14 years of age onward. They considered pesticide 




PD diagnosis was confirmed by in person examinations conducted by movement disorder 
specialists, thus minimizing the chance of misclassification of PD. Controls were selected 
by stratified random sampling of all AHS participants adjusted by age, sex, and state. A 
nested case-control design produced a control group with similar demographics (age, sex, 
state) and lifestyle factors (cigarette smoking), which reduced the chance of confounding. 
To compare overall pesticide use, they classified participants who used pesticides < 25 
lifetime days as unexposed and >25 lifetime days as exposed. 
 Tanner et. al found increased odds of PD with use of pesticides that inhibit the 
mitochondrial complex I (OR=1.7; 95% CI, 1.0-2.8) including rotenone (OR = 2.5, 95% 
CI 1.3-4.7) and also with use of pesticides that cause oxidative stress (OR = 2.0; 95% CI, 
1.2-3.6), including paraquat (OR = 2.5; 95% CI, 1.4-4.7).5 Interestingly, PD was 
diagnosed at a younger age among cases who used pesticides classified as oxidative 
stressors compared to those who used pesticides classified as complex I inhibitors (mean 
ages at PD diagnosis = 59 vs. 64 years, p =0.02).5 
 A weakness that the authors discuss in their study is the inclusion of cases already 
diagnosed with PD but still living during enrollment in the AHS. This implicated survival 
bias was a potential confounder. However, eliminating these living cases may have 
altered the power of this study or made it less generalizable.  
 A particular strength of the Tanner et al. study is that it defined pesticide 
exposure prior to disease onset. They analyzed rotenone use before PD diagnosis in cases 
and likewise during a comparable time period in healthy controls. Measuring pesticide 
exposure prospectively also reduces recall bias. This differs from epidemiological studies 
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that have analyzed the association between organic pesticides and PD risk only after PD 
had developed and been diagnosed, such as in Dhillon et al.  
 Using a case-control study of 100 cases and 84 controls from an East Texas 
population, Dhillon et al, analyzed the association of self-reported exposures to organic 
pesticides, such as rotenone, with PD. Their study found significantly increased odds of 
PD with use of organic pesticides, such as rotenone, in the past year in gardening (OR = 
10.9; 95% CI = 2.5–48.0) and any rotenone use in the past (OR = 10.0; 95% CI = 2.9–
34.3).30 Interestingly, investigators compared various pesticides but found the highest OR 
association with rotenone. In the interpretation of this finding, Dhillon et al. assumed that 
the pattern of pesticide use in the past year is to some extent reflective of the pattern of 
pesticide use in the past for cases. However, when analyzing rotenone use in the 
home/garden “ever” in the past the odds (OR=3.6) were increased but not significant 
(p=0.094).30 The significance of such a high OR for rotenone in the past year brings into 
question if cases created bias by affirming rotenone use already knowing they have PD. 
 To minimize recall bias from the possibility of overreporting exposures among 
cases they developed questions seeking information on rotenone and "organic pesticides" 
that were embedded throughout different sections of the questionnaire, instead of 
combining them in one section. The authors minimized diagnostic bias, or 
misclassification of disease, by confirming the cases and controls using the same 
neurologist specializing in movement disorders.   
 A particular strength of this study was that it sought to determine the association 
of PD with specific pesticides in contrast to past studies that instead investigated the 
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association of PD with pesticides broadly as a group. They found an increased odds (OR 
= 2.0) for exposure to chlorpyrifos products, a type of organophosphate insecticide. They 
also found an elevated odds (OR = 3.5, CI: 0.4–31.6) with exposure to paraquat.30 
However, the sample size reporting this exposure was small and the results were not 
statistically significant. Due to limited study power from small sample size (some control 
exposures have fewer than five observations), confidence intervals for some of the 
associations were wide, such as that for paraquat.   
Although most epidemiological studies have investigated the association between 
pesticide exposure and PD by using samples of unrelated individuals, a more recent study 
in 2008 undertook a family-based case-control approach. Hancock et al. recruited 319 PD 
cases and 296 relative controls between 2000-2006 from the Morris K. Udall PD 
Research Center of Excellence at Duke University Medical Center. Upon enrollment, the 
probands, the first affected individual in a family, were asked to contact their affected and 
unaffected relatives to request their participation. This included first degree relatives with 
or without PD, as well as their spouses. This allowed cases and relative controls to be 
well matched on genetic and demographic factors having been ultimately taken from the 
same population pool. However, being that the sample selection was not random this 
allowed for selection bias and undermined the generalizability of this study. Additionally, 
there is the potential for similar environmental exposures amongst family members with 
PD.  
 Pesticides were classified into specific functional types (i.e. insecticides, 
herbicides, and fungicides) by looking up the chemical or trade name of each reported 
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pesticide product in the Pesticide Action Network pesticides database to obtain the 
primary function and chemical class of its main ingredient.   
 This family-based case study found that individuals with PD were significantly 
more likely to report direct pesticide application than their unaffected relatives (OR=1.61; 
95% CI: 1.13–2.29). Frequency, duration, and cumulative exposure were also 
significantly associated with PD in a dose-response pattern (p ≤ 0.013).31 The strength of 
such a study is that it implicates pesticide exposure with development of sporadic PD. 
This study controlled for age-at-examination, sex, cigarette smoking, and caffeine 
consumption. The significance of this study is that associations between pesticides and 
PD were lower in those with positive family histories (OR=1.2; p=0.72) but were 
significant in those with negative family histories (OR=1.8; p<0.001). What this 
association suggests is that the etiology of PD for those with negative family histories 
was due solely to pesticide exposure and not genetics.  
 General pesticide exposure in the home or at work was assessed over the phone 
via a self-reporting survey. As this was a retrospective study, it was also subject to recall 
bias with cases reporting increased pesticide exposure compared to their unaffected 
relatives.   
 This study by Hancock et al. was too underpowered to analyze the effect of 
pesticides in those with a family history of PD. Thus, the possibility of pesticides and 




 However, the study highlights impressive results. The observed association 
between pesticides and PD, in comparison to other epidemiological studies, is not likely 
confounded by unmeasured genetic and environmental influences on exposure and the 
disease. Investigators of the study were able to minimize this by selecting from a 
population of individuals likely exposed to the same environmental factors and from the 
same genetic pool.   
 In addition, the observation that the strongest associations between PD and 
pesticides were obtained in families with no history of PD may suggest that family 
history of PD may be a confounding variable in future studies of the effects of pesticides 
on PD.32 Families without a history of PD contain individuals who may harbor genetic 
variants that on their own are not sufficient to cause disease but, rather, increase the 
susceptibility for disease development when exposed to an environmental insult, such as 
pesticide exposure. This finding supports the double hit theory, meaning that pesticide 
exposure may alter or accelerate the effect of genetic susceptibility factors and ultimately 
lead to sporadic PD. This study emphasizes the need to consider pesticides as an effect 
modifier in future candidate gene studies. 
 
Elbaz et al. chose to study the association between PD and pesticides in a 
population characterized by a high prevalence of exposure. This community-based case-
control study was conducted using participants covered under the Mutualité Sociale 
Agricole (MSA), the French health insurance for workers in agriculture and related 
occupations while active or retired. This study included: farm owners and workers; 
workers in silos, agricultural cooperatives, seed shops; and tertiary sector professionals. 
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To confirm PD diagnosis, participants were examined in person by a movement disorder 
neurologist. When in person exams were not possible, patients’ neurologists were 
contacted. In total, 224 PD cases from the MSA were matched to 557 controls free of PD. 
Pesticide exposure was assessed using a 2‐phase procedure, including a case‐by‐case 
expert evaluation.33  
 They did not ask participants about exposure to PPE, making a point that farmers 
are likely to over-report their use when interviewed by occupational physicians. This may 
be a potential contributor as to why PPE use was found to have a higher association with 
PD risk in the PEG study.28  
 Like other studies, investigators here used the MMSE and restricted analyses to 
those with the highest scores so as to limit errors in recall, especially when reporting 
pesticides brand names and duration or frequency of exposures.  
Analyses of the association between PD and professional exposure to pesticides 
were first performed overall and by broad category (insecticides, fungicides, herbicides). 
They found a positive association between PD and overall professional pesticide use 
(OR=1.8, 95% CI = 1.1–3.1) with a dose‐response relationship observed for the number 
of years of use (p = 0.01). In men, increased odds of PD were associated with insecticides 
(OR = 2.2, 95% CI = 1.1–4.3), in particular organochlorine insecticides (OR = 2.4, 95% 
CI = 1.2–5.0). These associations were stronger in men with older onset PD than in those 
with younger onset PD and were characterized by a dose‐response relationship in the 
older group.33 Thus, their results suggest that genetic susceptibility may play a stronger 
role in younger onset PD cases, whereas environmental factors play a stronger role for 
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older onset PD cases. The authors of this study investigated alternative explanations for 
this incidental observation. One might argue that cases with older onset may have been 
exposed for more years than those with a younger onset. However, this was ruled 
unlikely because the number of years of exposure was similar between both groups for 
specific families of pesticides and the cumulative lifetime hours of exposure were 
generally greater for younger onset cases. Higher exposure levels in younger onset cases 
are likely due to increasing use in more recent decades. It is possible that younger 
subjects may have been more educated with respect to pesticides than older subjects 
leading them to take more precautions while spraying. 
 Accounting for exposure to multiple pesticides is always a challenge during 
analysis of these types of studies. To combat this, Elbaz et al. used a traditional chemical 
classification to define groups of participants exposed to pesticides sharing chemical 
characteristics. This led to larger group sizes than if they had considered individual 
pesticides separately. This could contribute to the observation that organochlorines had 
the strongest association with PD. It is possible that this study’s lack of association with 
other pesticide groups, which were reported less frequently as exposures than 
organochlorines, may actually be due to insufficient power of the study.33  
 Elbaz et al. did not find an association between PD and paraquat, an unexpected 
finding in epidemiological studies investigating the matter. The investigators of this study 
proposed a potential reason for this unexpected result was that in France, paraquat was 
mainly used as a nonselective herbicide to kill weeds around the fields, thus resulting in 
lower exposure levels compared to other herbicides. They also proposed that paraquat 
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may be associated with PD only among genetically susceptible individuals, making a 
genetic-environment link more likely for paraquat and PD. However, it is difficult to 
know if individuals are genetically susceptible before they are exposed to a pesticide 
given the lack of reliable biomarkers or genetic tests for PD. Toxicological studies have 
also suggested that maneb and paraquat act synergistically to produce Parkinsonian 
effects. However, their analysis did not find a statistically significant association between 
PD and maneb. They were unable to provide data regarding maneb and paraquat 
combination used on PD. This brings into question the power and sample size used in this 
study for the cases who were exposed to both maneb and paraquat.   
Costello et al. took yet another approach. The authors of this study developed an 
exposure assessment tool based on geographic information systems that integrated 
information from California Pesticide Use Reports and land-use maps to estimate 
historical exposure to agricultural pesticides in the residential environment. Between 
1998-2007, they enrolled 368 incident PD cases and 341 population controls from the 
Central Valley, California in a case-control study. They found that exposure to pesticides 
maneb and paraquat within 500 m of the home increased PD odds by 75% (OR=1.75, 
95% CI 1.13-2.73).34   
In contrast to the age-exposure relationship seen in the previous study, younger 
individuals (<60 years) at the time of diagnosis had much higher odds of PD with 
exposure to maneb or paraquat alone (OR=2.27, 95% CI: 0.91, 5.70) or to both pesticides 
combined (OR=4.17, 95% CI: 1.15, 15.16).34 Such a study provides evidence that the 
combination of maneb and paraquat increases PD risk, potentially acting synergistically 
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to become neurotoxic, and particularly when exposures occur at younger age. Persons 
living near fields sprayed with maneb and paraquat may also be exposed to other 
agricultural chemicals. However, when investigators adjusted for other pesticides as a 
potential confounder, this did not remove the statistically significant association for 
maneb and paraquat in PD risk.34 
 A weakness to the study is based on their GIS model. Although it allowed 
investigators to calculate the number of pounds of each active ingredient applied per acre 
within a 500-m buffer, these quantities and their relative levels of toxicity are not 
comparable across pesticides nor is this method a direct measure of exposure. The 
authors legitimize their model by the fact that no information currently exists allowing 
for standardization of their measures.  
A number of studies have investigated the association between PD risk and 
exposure to individual pesticides (rotenone vs. paraquat) or specific groups of pesticides 
(herbicides vs. insecticides). Other studies have investigated the association between PD 
and the mechanism of neurotoxicity behind similar functional pesticides. Despite their 
differences in study design, the results of such studies provide evidence for increased risk 
of PD with pesticide exposure. The strengths of the studies reviewed above include 
strong methods for determining disease diagnosis, using questionnaires, telephone 
interviews, and in person Neurologic assessments by licensed Movement Disorder 
specialists. The most common weakness, however, remains the method in which 
pesticide exposure is classified or legitimized. It is possible that many studies have used 
inaccurate or indirect measures of pesticide exposure. This makes it more difficult to 
 
40 
draw firm conclusions about any specific pesticide definitively linked to PD 
development. Additionally, future studies should include large numbers of participants 
when possible in order to have sufficient power to detect a significant difference in 
exposure. The reason some of the associations between pesticides and PD have failed to 
show significance in data may largely be due to strictly defined inclusion/exclusion 
criteria and small sample size. A prospective study would be ideal in order to limit recall 
bias, but may prove to be difficult given lack of reliable biomarkers and unknown time 
from exposure to clinical symptoms. More importantly, detailed and accurate 
quantifications of pesticide exposure must be determined in order for studies to come to 







The proposed study will be a nested case-control study using participants from a 
large cohort, those recruited in the Agricultural Health Study (AHS). The AHS was a 
collaborative study comprised of investigators from the National Cancer Institute, the 
National Institute of Environmental Health Sciences, the Environmental Protection 
Agency, and the National Institute for Occupational Safety and Health. It was started in 
order to better understand how agricultural, lifestyle and genetic factors affect the health 
of farming populations. Participants of the AHS included licensed pesticide applicators, 
as well as their spouses, living in Iowa and North Carolina. Participants completed an 
enrollment questionnaire on farming, pesticide use, lifestyle factors, and health status. 
There have been several phases imposed to follow up and collect information from 
participants since then. Follow up telephone interviews updated exposure information as 
well as changes in health status and new disease diagnoses.  
By choosing participants from the AHS the proposed study will have a large 
cohort to choose participants from. The benefit of using the AHS includes access to its 
accurately, pre-collected data on pesticide exposure through farming (occupational 
exposures). Because the data collected by AHS is ongoing and dates back to 1993 this 
study will have the advantage of studying PD as an outcome after working with 




Study population and sampling 
The population studied will be selected from licensed private pesticide applicators 
and their spouses. Applicators will be selected from AHS records and separated into 
those with PD as cases and those without PD as controls. The AHS is an 89,000-member 
cohort of licensed pesticide applicators and their spouses enrolled in Iowa and North 
Carolina from 1993–1997.  
Controls will be frequency-matched to cases by age grouped by decade (< 40, 40–
49, 50–59, 60-69, ≥ 70 years), sex, state (Iowa, North Carolina), years of education, (<12 
years, 12 years, >12 years) and smoking status (ever/never). Smoking status will be 
referenced as “ever” if the participant has smoked >100 cigarettes during their lifetime.  
Matching cases and controls by demographics will serve to minimize confounding 
variables in our study.  
The estimated sample size (with continuity) to have 80% power at an alpha of 
0.05 will be 79 cases and 237 controls. Sample size calculations were estimated based on 
the study by Tanner et al. which also used participants from the AHS database. 
Participants will be pulled based on whether they have PD or not. Since PD is a fairly 
rare disease, there are more participants without PD than with and, thus, my study will 
match the number of controls to cases in a 3:1 ratio. The study by Tanner et al. found 358 
potential controls after screening and 110 confirmed PD cases, which further supports 
this 3:1 ratio. The risk of exposure in controls is estimated to be 0.66 given that Tanner et 
al. found 542 potential controls eligible after screening and 358 controls with pesticide 
exposure. The odds in this study was increased for paraquat (OR=2.5, 95% CI 1.4-4.7) 
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Cohort members who are ultimately diagnosed with PD, other forms of 
parkinsonism, other neurological disease, dead, cognitively impaired, or seriously ill will 
not be eligible to serve as controls.  
Those with family history will be excluded from our study to avoid potential 
confounding by genetics. Family history of PD will be considered positive if the 
participant has any first-degree relative diagnosed with PD. 
 
Exposure of Interest 
The exposure of interest will be rotenone and paraquat occupational use in both 
cases and controls. The outcome being measured will be the development of PD in those 
exposed to either paraquat or rotenone. Participants exposed to both in pesticides will be 
excluded in order to avoid the potential for synergism. The study will investigate long 
term exposure of either pesticide in farm workers. Farmers will have used either pesticide 
daily for a number of years. They will have reported this data back to the investigators 
part of the AHS, from which this study will collect this information. 
 
Study variables and measures 
The AHS gathered information from 89,655 private and commercial pesticide 
applicators and their spouses from Iowa and North Carolina. Participants were recruited 
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from 1993-1997 in Phase 1 of the study. Active follow up efforts were conducted in 
1999-2003 for Phase 2, 2005-2010 for Phase 3, and 2013-2015 for Phase 4.  Upon 
enrollment in Phase 1, participants filled out questionnaires that defined their 
demographics (age, sex, race, marital status), lifestyle, medical history, and pesticide use. 
There was also a separate form for spouses to complete separately.  
The Phase 2 interview was completed by 64% of private applicators, 59% of 
commercial applicators, and 74% of spouses. During phase 1, questionnaires were 
utilized to provide updated information on farming practices, lifestyle, and health. 
Additionally, this follow up collected data on diet and asked for a sample of cheek cells 
as a source of DNA.  
Active follow-up in Phases 3 and 4 was restricted to private applicators and 
spouses who had completed Phase 1 and 2. The follow up questionnaires in Phases 3 and 
4 collected more extensive pesticide exposure data from participants. Phase 3 was 
completed by 46% of enrolled private applicators and 61% of enrolled spouses. Phase 4 
was completed by 47% of the enrolled private applicators and 61% of enrolled spouses. 
Due to a lower percentage of participants completing the latter Phases of the AHS, our 
study will pull data of participants from Phases 1 and 2 only.  
Our study will specifically look at the enrollment questionnaire and take-home 
applicator from Phase 1 for demographics. It will also look at Phase 1 and 2 for 
information on application methods of paraquat and rotenone as well as mixing or 
preparation of paraquat and rotenone. Phase 1 will also provide information on duration 
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of use for these pesticides from the 1940s-1990s, hours worked per day, and years of 
working with pesticides, as well as living conditions. Phase 2 provided updated 
information on pesticide use and health changes. Tanner et al. recruited participants only 
from Phase 1, providing our new study with additional information and a larger sample 
size. 
The main explanatory variable being measured will be if pesticide exposure, 
particularly paraquat and rotenone, have an association with increased risk of PD.  For 
each pesticide, to constitute means of “exposure” the investigators will analyze the AHS 
data of Phase 1 to determine “ever use” of the pesticide (used one or more times) and 
“lifetime days of use” (determined for each farm job by multiplying years of use by 
average days of use per year and then summing across jobs).  Cases and controls will be 
frequency matched by demographics to eliminate the chance for confounding.  
  
Recruitment 
The participants will be selected from a cohort of 89,655 licensed private pesticide 
applicators (mainly farmers) and their spouses previously enrolled in the AHS. Using the 
AHS database of study participants, pesticide applicators with suspected PD will be 
recruited and consented by telephone. Phase 1 and 2 questionnaires both ask about health 
related changes including PD related symptoms. The AHS database keeps updated follow 




Individuals with suspected PD will be identified using the health data collected 
from phase 1 and 2. These suspected cases will be interviewed by telemedicine phone or 
video by Neurologists able to recognize the classic symptoms of Parkinson’s Disease. 
Participants selected over the phone will be followed up in person with physical exams 
performed by Neurologists and Movement Disorder Specialists.  
 Controls will be selected by matching to cases using the AHS database. To rule 
out a diagnosis of PD, they will also be assessed by telemedicine interview and subject to 
an in person physical exam by a Neurologist.  
 The in-person assessment will include current clinical criteria used to diagnose 
PD and to distinguish PD from other disorders, including a standardized medical and 
neurological history, the Cognitive Abilities Screening Instrument (to assess for cognitive 
decline) a standardized videotaped assessment of parkinsonism, a handwriting sample, 
and medication reconciliation. Established criteria for PD will be used: Bradykinesia and 
at least one of the following: 1) muscular rigidity; 2) tremor; 3) postural instability. 
Physical assessments by Neurologists will include a standardized neurological 
examination, orthostatic hypotension assessment, the Unified Parkinson’s Disease Rating 
Scale published by the International Parkinson and Movement Disorder Society.35  
Following any assessment of a control with an exam suggesting parkinsonism, the 
history and exam will be repeated and confirmed by another licensed neurologist. 
Diagnosis for all suspect cases and when PD is suspected in controls will be determined 
by agreement of at least two neurologists after independent review of all available 
diagnostic information including medical records, in-person examination records, and 
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videotaped examination. Any controls found to have incidental PD or who develop early 
PD during the study will be converted into a case.  
 
Data collection 
The majority of data collection will be obtained from the AHS database directly. This 
includes the categorical variables to which cases and controls are matched (age, sex, 
ethnicity, smoking status). This also includes measures of rotenone or paraquat pesticide 
use, duration of use, methods of pesticide application and mixing. 
 
 
Data analysis  
The association between PD and exposure to paraquat or rotenone will be determined by 
odds ratio (OR) and 95% confidence intervals (CIs). Duration of either pesticide use and 
measurement of exposure will depend on the answers provided by participants 
questionnaires. Data will be analyzed using SPSS version 13.0. 
Following data analysis of our study, the expected results will show an 
association between PD and either paraquat or rotenone pesticide exposure. Given 
analysis of duration (defined by years) of pesticide use there will also be an expected 
increase in PD as duration of pesticide use increases.  
Being that the cases and controls will be frequency matched by categorical 





PPE use will not be included as a variable in the analysis for several reasons. It is likely 
that farmers may over report or under report their actual PPE use. PPE use may prompt 
farmers to use higher concentrations of pesticides resulting in confounding on its effect. 
PPE use is also difficult to classify equally amongst self-reports (i.e. differences in PPE 
quality and quantity). 
 
Timeline and resources 
The timeline of this study will take place over 1-1.5 years. This will allow time for IRB 
review, which we estimate will take 1-2 months. Recruitment and data collection from 
the AHS will take 6 months to organize. Analysis of this data will likely take an 
additional 6 months given the methodology and large study size.  
 The resources required for the study include Neurologists and Movement 
Disorder specialists. These specialists must be available both over the telephone and to do 
“in house” assessments in Iowa, and North Carolina. Technicians may be trained to 
assess controls in person. Agreement of agricultural and epidemiological organizations 
and particularly the AHS investigators, is required. The primary investigator will allocate 
chief investigators, 2 per state, who in turn will coordinate with Neurologists, movement 
disorder specialists, and technicians.  
 Computer software is required, but minimal. Chief investigators will review and 




Institutional Review Board 
This study will submit an Exempt Category 4 application to the Boston University 
Medical Campus Institutional Review Board (BUMC IRB). Under this category consent  
is not required for secondary research of identifiable private information or identifiable 
biospecimens. The reason for Exempt Category 4 is that there is very minimal or no risk 
to the participants of the study because this a nest study looking at pre-collected data by 
the AHS. The neurological exam will be obtained anonymously without inclusion of the 
patient’s true name. The Exempt Category 4 application will be for permission to involve 
human participants in an observational case control study on the effects of pesticide use, 
particularly paraquat and rotenone, on Parkinson’s disease. This requires use of protected 
health information (PHI) as investigators will need to access participants questionnaire 
responses and telephone records as well as review physical exams of participants 
recorded on tapes. Board certified Neurologists will evaluate cases and controls for PD. 
Any controls found to have incidental PD will be informed by the Neurologist evaluating 







The pathogenesis of PD is thought to involve several identified pathways, of 
which a combination of genetic and environmental factors plays a role. Exposures 
leading to genetic changes may occur years or even decades before diagnosis. Many 
individuals with early or mild PD may die from other medical comorbidities before motor 
symptoms manifest. Additionally, not everyone with PD is affected with the same type, 
or severity, of clinical features. The variability of disease and progression suggests that 
PD is a heterogenous disease with multiple etiologies. Environmental effects can no 
longer be ignored, especially those involving pesticide exposures.  
 Evidence has long supported that pesticides play a major role in the pathogenesis 
of PD in animal models with real-life associations in farm workers. Studies have since 
explored the mechanisms behind pesticides exhibiting their neurotoxic effects. Of 
particular importance is the dysfunction of the mitochondrial respiratory chain and the 
production of reactive oxygen species, implicated in paraquat and rotenone respectively. 
Because paraquat and rotenone remain two of the most widely used pesticides in the 
U.S., implications of pesticides on PD risk has great public health significance. 
 Our study builds on previous studies discussed in the existing research section 
that also investigate the association between pesticides and PD. The studies reviewed 
here have had significant results calling for further investigation using greater sample 
sizes and a more generalizable cohort. Some of their limitations include small sample 
sizes and variations in pesticide exposure assessment methods. For example, many 
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studies have implicated the use of paraquat to be related to increased PD risk but were 
unable to show statistical significance. This may be due to insufficient sample sizes, 
confounding from other exposures of different pesticide classes or other variables that are 
difficult to measure. 
 Epidemiological studies on pesticide exposure and PD are particularly limited by 
the lack of a clear, detailed exposure assessment. Most people using pesticides in the 
home or garden typically cannot distinguish between which compounds they were 
exposed to because there are a variety of product trade names and mixtures. This poses a 
problem for studies to assess and narrow down exposures to specific agents. Only a few 
recent studies have collected sufficient data on the frequency, duration, and use of 
individual pesticides allowing dose-response relationships to be measured, as well as 
specific pesticides, not groups, to be linked to PD. My study will omit pesticide 
exposures in the home from data analysis to limit this problem and be powered enough to 
detect differences in the pesticides of interest.  
 A major confounding variable discussed in other epidemiological studies is the 
exposure of multiple pesticides at once. I foresee this being a problem in our study, as 
most farmers do not typically work with one single class of pesticide, rather with multiple 
types. Our investigators recognize that other pesticides may be implicated in developing 
PD and multiple pesticide use may superimpose the risk of PD on the applicator. Our 
study will attempt to eliminate this potential confounder by looking at paraquat and 
rotenone use only. Information on other pesticide use will be gathered and the data will 




A potential bias in our study will be any diagnosis of incidental PD in controls when 
Neurologists conduct the telemedicine and in person medical analysis. Because our study 
evaluates the onset of PD after establishing strict criteria for pesticide use, this could 
mean that the incidental finding of PD has less potential to introduce bias.  
 Strengths of this study will include minimal opportunity for misclassification of 
disease in cases and controls by installing a strict screening process over telemedicine 
and reinforced by in person examinations. By using the cohort data produced by AHS for 
exposure, our results are less likely to be subject to recall bias since the data was gathered 
contemporaneously. The recall bias seen in other studies was introduced by methods 
gathering pesticide exposure data after the diagnosis of PD was made.  
 Our study will pull information from Phase 1 and Phase 2 of the AHS 
questionnaire database. This allows our study access to accurate data on pesticide 
exposures over a period of time. The advantages of this method gives our study the 
opportunity for a larger sample size and also makes it generalizable to the greater 
population. If we had included all four phases of the AHS our study would have had 
more measures for accurate and contemporary pesticide data but would have been less 
generalizable and increased potential for sample bias.  
 
Summary 
Identification of several genes implicated in the pathogenesis of Parkinson’s 
disease has led to better understanding of the molecular mechanisms defining the disease. 
However, there continues to be lack of consistency in terms of genetics and who will get 
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the disease. Not everyone with these specific gene mutations will inherit PD and there 
have been many more sporadic cases reported than inherited. This has directed research 
in PD towards the impact of environmental factors or, more specifically, one’s genetic 
susceptibility compounded by environmental exposures in the etiology of PD.  
Populations highest at risk for pesticide exposures include farmers or migrant 
workers, those drinking well water near sites with pesticide exposure, and family 
members of such workers. Additionally, occupational pesticide applicators often find 
themselves living close to where they work every day. For this reason, pesticides have 
been extensively studied and the methods of neurotoxicity have been recreated in animal 
models. 
 
Clinical and/or public health significance 
It is apparent that pesticide exposures may exhibit strong neurotoxic effects, 
especially dependent on age and frequency of exposure. According to EPA estimates, 
occupational exposure to pesticides poisons as many as 20,000 farmworkers every year. 
However, numbers are likely much higher than reported due to the inability of affected 
workers to get medical care, medical misdiagnosis, and the absence of a coordinated 
national incident reporting system (pesticide exposure reporting is generally state 
regulated). Populations that are most vulnerable to the effects of pesticides are 
farmworkers and their families, who are subject to direct contact with these chemicals. 
Additionally, occupational workers who spray pesticides generally live in or close to the 
regions where these chemicals are used and are exposed to its effects every day in the soil 
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and water systems. If PD risk is truly associated with exposure to pesticides such as 
paraquat and rotenone, this must be properly proven and federal regulations enacted to 
ban such chemicals from use. In that case, measures must be instilled to prevent exposure 
to pesticides, especially given that many continue to be extensively used worldwide. If 
this study were to implicate the use of paraquat and rotenone in the risk of PD there could 
be major changes in pesticide regulations and use mandated by the U.S. government and 
governments worldwide. This study will have significant public health implications in 
furthering and possibly contributing new data that links paraquat and rotenone to PD.  
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